EP1889842A4 — Heterocyclic compound
Assigned to Japan Tobacco Inc · Expires 2009-07-29 · 17y expired
What this patent protects
A compound represented by the general formula (1') or a salt thereof; and a therapeutic or prophylactic agent for a glucocorticoid-related condition or an 11βHSD1 inhibitor comprising the compound of the salt thereof: (1') wherein the ring A, R2, R3, R4 and X are as defined in th…
USPTO Abstract
A compound represented by the general formula (1') or a salt thereof; and a therapeutic or prophylactic agent for a glucocorticoid-related condition or an 11βHSD1 inhibitor comprising the compound of the salt thereof: (1') wherein the ring A, R2, R3, R4 and X are as defined in the description.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.